Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.43 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.39 |
| ▸ | TMPRSS15 | P98073 | 3/20 | 0.39 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2327018 | 0.89 | MME (0.49) | ACEPRSS1TMPRSS15MME | |
| SCHEMBL2327014 | 0.89 | MME (0.49) | ACEPRSS1TMPRSS15MME | |
| SCHEMBL2328079 | 0.84 | ALDH1A1 (0.49) | ACEENPEPKEAP1NFE2L2MME | |
| SCHEMBL2327976 | 0.82 | ENPEP (0.41) | ACEENPEPKEAP1NFE2L2PRSS1 | |
| SCHEMBL10658891 | 0.78 | CA2 (0.51) | — | |
| SCHEMBL10658899 | 0.78 | CA2 (0.51) | — | |
| SCHEMBL13583683 | 0.77 | MMP8 (0.47) | MME | |
| SCHEMBL13583695 | 0.77 | MMP8 (0.47) | MME | |
| SCHEMBL2330723 | 0.76 | CNR2 (0.50) | KEAP1NFE2L2 | |
| SCHEMBL2323705 | 0.75 | MME (0.54) | ENPEPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356979-B1 | ANTI-WRINKLE AGENTS | POLA CHEM IND INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| EP-3173063-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2017-05-31 | — | — | EP | disclosed |
| US-8835498-B2 | Anti-wrinkle agents | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20110245343-A1 | ANTI-WRINKLE AGENTS | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| EP-2356979-A1 | ANTI-WRINKLE AGENTS | Pola Chemical Industries Inc. (JP) | 2011-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245343-A1 | ANTI-WRINKLE AGENTS | GLA, H1-4, H1-3 | ACE 4738/4885ENPEP 3287/4885KEAP1 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.